false0001651308
0001651308
2020-01-24
2020-01-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 8-K
_________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): January 24, 2020
BEIGENE, LTD.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
|
Cayman Islands
|
001-37686
|
98-1209416
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand Cayman KY1-1108
Cayman Islands
(Address of Principal Executive Offices) (Zip Code)
+1 (345) 949-4123
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
|
|
BGNE
|
|
The NASDAQ Global Select Market
|
|
Ordinary Shares, par value $0.0001 per share*
|
|
06160
|
|
The Stock Exchange of Hong Kong Limited
|
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01. Other Events.
BeiGene, Ltd. (the “Company”) disclosed today at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) being held in San Francisco, that the Company plans to convert from Phase 3 to Phase 2 the clinical trial of its PARP inhibitor pamiparib vs. placebo as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer who have responded to platinum-based first line chemotherapy (NCT 03427814; also known as the BGB-290-303 trial). The trial has enrolled approximately 120 patients globally since it commenced in July 2018, and the enrollment has been slower than expected. The reason for this change is not due to safety or efficacy issues. The Company plans to evaluate data from the Phase 2 trial to assess the potential of pamiparib in this indication and the potential next steps of development as a monotherapy or in combination with other therapies.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
|
|
|
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
104
|
|
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
|
Exhibit Index
|
|
|
|
|
|
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
104
|
|
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BEIGENE, LTD.
|
|
|
|
|
|
Date: January 24, 2020
|
By:
|
/s/ Scott A. Samuels
|
|
|
Name:
|
Scott A. Samuels
|
|
|
Title:
|
Senior Vice President, General Counsel
|